Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04225871 · ClinicalTrials.gov registry record · Phase 3
Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis
A Phase 3 study of Generalized Myasthenia Gravis, sponsored by UCB Biopharma SRL.
- Active
- Registry status
- Phase 3
- Development phase
- 200
- Enrollment target
- 20
- Study locations
NCT04225871: Active Phase 3 study of Generalized Myasthenia Gravis, sponsored by UCB Biopharma SRL.
NCT04225871 is a Phase 3 study of Generalized Myasthenia Gravis that is active but no longer recruiting, run by UCB Biopharma SRL. The registered enrollment target is 200 participants, above the 123-participant average among 26 other Generalized Myasthenia Gravis trials with a reported enrollment target (63% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04225871, a Phase 3 study of Generalized Myasthenia Gravis, is active but no longer recruiting, sponsored by UCB Biopharma SRL.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
The RAISE-XT study is an open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gMG who have previously participated in a qualifying Ra Pharmaceuticals sponsored zilucoplan study.
Primary Outcome
A treatment-emergent adverse event is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication.
Conditions Studied
Interventions
- DRUG zilucoplan (RA101495)
Study Locations (20)
California
- Mg0011 31 - Irvine
- MG0011 4 - Los Angeles
- Mg0011 220 - Pasadena
- Mg0011 160 - San Francisco
New York
- Mg0011 30 - Buffalo
- Mg0011 123 - Great Neck
- Mg0011 23 - New York
Michigan
- Mg0011 33 - Detroit
- Mg0011 49 - East Lansing
Alabama
- Mg0011 41 - Mobile
Arizona
- Mg0011 116 - Phoenix
Connecticut
- Mg0011 24 - New Haven
District of Columbia
- Mg0011 27 - Washington D.C.
Florida
- Mg0011 25 - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2019-12-23 |
| Est. Completion | 2026-06-02 |
| Phase | Phase 3 |
What the registry record for NCT04225871 still lists
NCT04225871 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 123-participant average among 26 other Generalized Myasthenia Gravis trials with a reported enrollment target (63% higher).
The record links to 1 condition, with Generalized Myasthenia Gravis appearing as the primary indexed condition, and to 1 intervention - of which zilucoplan (RA101495) is the first listed.
NCT04225871 names 20 study sites across 14 states, led by California, New York, Michigan.
Frequently Asked Questions
What is clinical trial NCT04225871 about?
NCT04225871 is a clinical study titled "Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis". The RAISE-XT study is an open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gMG who have previously participated in a qualifying Ra Pharmaceuticals sponsored zilucoplan study.
What is the current status of trial NCT04225871?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2019-12-23. Estimated completion is 2026-06-02.
What conditions does trial NCT04225871 study?
This clinical trial studies the following conditions: Generalized Myasthenia Gravis.
What interventions are being tested in trial NCT04225871?
The interventions under investigation include: zilucoplan (RA101495) (DRUG).
Who is sponsoring clinical trial NCT04225871?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04225871 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Generalized Myasthenia Gravis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04225871's enrollment target sits among peer trials
200 7th of 26 higher than 19 of 26 other Generalized Myasthenia Gravis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Generalized Myasthenia Gravis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
RECRUITING · Phase 3
-
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
RECRUITING · Phase 3
-
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
RECRUITING · Phase 3
-
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
RECRUITING · Phase 3
-
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI